目的 探讨血浆置换联合连续性血液净化在救治难治性川崎病休克综合征（Kawasaki disease shock syndrome，KDSS）中的作用。 方法 收集2019年1月—2022年8月在湖南省儿童医院重症医学科住院治疗的35例KDSS患儿为研究对象，按照是否实施血浆置换+连续性静脉-静脉血液滤过透析治疗分为净化组（12例）和常规组（23例），比较两组患儿的临床资料、实验室指标及预后情况。 结果 净化组患儿休克恢复时间、重症监护病房住院时间均短于常规组，病程中脏器受累个数少于常规组（P<0.05）。净化组血液净化治疗后血白细胞介素-6、肿瘤坏死因子α、肝素结合蛋白、脑钠肽水平较血液净化治疗前均下降（P<0.05），而常规组治疗后这些指标较治疗前升高（P<0.05）。净化组患儿治疗后每搏输出变异、胸腔液体水平、外周血管阻力均随时间推移呈下降趋势，心输出量随着治疗呈上升趋势。 结论 血浆置换联合连续性静脉-静脉血液滤过透析治疗KDSS可减轻炎症反应，平衡血管内外的液体平衡，缩短病程、休克时间及重症监护病房住院时间。
Abstract
Objective To study the role of plasma exchange combined with continuous blood purification in the treatment of refractory Kawasaki disease shock syndrome (KDSS). Methods A total of 35 children with KDSS who were hospitalized in the Department of Pediatric Intensive Care Unit, Hunan Children's Hospital, from January 2019 to August 2022 were included as subjects. According to whether plasma exchange combined with continuous veno-venous hemofiltration dialysis was performed, they were divided into a purification group with 12 patients and a conventional group with 23 patients. The two groups were compared in terms of clinical data, laboratory markers, and prognosis. Results Compared with the conventional group, the purification group had significantly shorter time to recovery from shock and length of hospital stay in the pediatric intensive care unit, as well as a significantly lower number of organs involved during the course of the disease (P<0.05). After treatment, the purification group had significant reductions in the levels of interleukin-6, tumor necrosis factor-α, heparin-binding protein, and brain natriuretic peptide (P<0.05), while the conventional group had significant increases in these indices after treatment (P<0.05). After treatment, the children in the purification group tended to have reductions in stroke volume variation, thoracic fluid content, and systemic vascular resistance and an increase in cardiac output over the time of treatment. Conclusions Plasma exchange combined with continuous veno-venous hemofiltration dialysis for the treatment of KDSS can alleviate inflammation, maintain fluid balance inside and outside blood vessels, and shorten the course of disease, the duration of shock and the length of hospital stay in the pediatric intensive care unit.
关键词
川崎病休克综合征 /
血浆置换 /
连续性静-静脉血液滤过透析 /
儿童
Key words
Kawasaki disease shock syndrome /
Plasma exchange /
Continuous veno-venous hemofiltration dialysis /
Child
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
1 Huang WC, Huang LM, Chang IS, et al. Epidemiologic features of Kawasaki disease in Taiwan, 2003-2006[J]. Pediatrics, 2009, 123(3): e401-e405. PMID: 19237439. DOI: 10.1542/peds.2008-2187.
2 Kanegaye JT, Wilder MS, Molkara D, et al. Recognition of a Kawasaki disease shock syndrome[J]. Pediatrics, 2009, 123(5): e783-e789. PMID: 19403470. PMCID: PMC2848476. DOI: 10.1542/peds.2008-1871.
3 Harada T, Ito S, Shiga K, et al. A report of two cases of Kawasaki disease treated with plasma exchange[J]. Ther Apher Dial, 2008, 12(2): 176-179. PMID: 18387169. DOI: 10.1111/j.1744-9987.2008.00566.x.
4 Miao H, Cui Y, Wang F, et al. Continuous hemofiltration plus plasma exchange in patient with Kawasaki disease shock syndrome: a case report and literature review[J]. Ann Clin Lab Sci, 2019, 49(6): 829-834. PMID: 31882435.
5 McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association[J]. Circulation, 2017, 135(17): e927-e999. PMID: 28356445. DOI: 10.1161/CIR.0000000000000484.
6 Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3)[J]. JAMA, 2016, 315(8): 801-810. PMID: 26903338. PMCID: PMC4968574. DOI: 10.1001/jama.2016.0287.
7 Khwaja A. KDIGO clinical practice guidelines for acute kidney injury[J]. Nephron Clin Pract, 2012, 120(4): c179-c184. PMID: 22890468. DOI: 10.1159/000339789.
8 Li Y, Zheng Q, Zou L, et al. Kawasaki disease shock syndrome: clinical characteristics and possible use of IL-6, IL-10 and IFN-γ as biomarkers for early recognition[J]. Pediatr Rheumatol Online J, 2019, 17(1): 1. PMID: 30611297. PMCID: PMC6321686. DOI: 10.1186/s12969-018-0303-4.
9 Ma L, Zhang YY, Yu HG. Clinical manifestations of Kawasaki disease shock syndrome[J]. Clin Pediatr (Phila), 2018, 57(4): 428-435. PMID: 28905639. DOI: 10.1177/0009922817729483.
10 Gamez-Gonzalez LB, Moribe-Quintero I, Cisneros-Castolo M, et al. Kawasaki disease shock syndrome: unique and severe subtype of Kawasaki disease[J]. Pediatr Int, 2018, 60(9): 781-790. PMID: 29888440. DOI: 10.1111/ped.13614.
11 Fujimaru T, Ito S, Masuda H, et al. Decreased levels of inflammatory cytokines in immunoglobulin-resistant Kawasaki disease after plasma exchange[J]. Cytokine, 2014, 70(2): 156-160. PMID: 25082649. DOI: 10.1016/j.cyto.2014.07.003.
12 Sonoda K, Mori M, Hokosaki T, et al. Infliximab plus plasma exchange rescue therapy in Kawasaki disease[J]. J Pediatr, 2014, 164(5): 1128-1132.e1. PMID: 24560183. DOI: 10.1016/j.jpeds.2014.01.020.
13 Hokosaki T, Mori M, Nishizawa T, et al. Long-term efficacy of plasma exchange treatment for refractory Kawasaki disease[J]. Pediatr Int, 2012, 54(1): 99-103. PMID: 22004042. DOI: 10.1111/j.1442-200X.2011.03487.x.
14 Chen LX, Demirjian S, Udani SM, et al. Cytokine clearances in critically ill patients on continuous renal replacement therapy[J]. Blood Purif, 2018, 46(4): 315-322. PMID: 30107381. DOI: 10.1159/000492025.
15 Park JT, Lee H, Kee YK, et al. High-dose versus conventional-dose continuous venovenous hemodiafiltration and patient and kidney survival and cytokine removal in sepsis-associated acute kidney injury: a randomized controlled trial[J]. Am J Kidney Dis, 2016, 68(4): 599-608. PMID: 27084247. DOI: 10.1053/j.ajkd.2016.02.049.
16 Quinto BMR, Iizuka IJ, Monte JC, et al. TNF-α depuration is a predictor of mortality in critically ill patients under continuous veno-venous hemodiafiltration treatment[J]. Cytokine, 2015, 71(2): 255-260. PMID: 25461406. DOI: 10.1016/j.cyto.2014.10.024.
17 Alobaidi R, Morgan C, Basu RK, et al. Association between fluid balance and outcomes in critically ill children: a systematic review and meta-analysis[J]. JAMA Pediatr, 2018, 172(3): 257-268. PMID: 29356810. PMCID: PMC5885847. DOI: 10.1001/jamapediatrics.2017.4540.
18 Miklaszewska M, Korohoda P, Zachwieja K, et al. Factors affecting mortality in children requiring continuous renal replacement therapy in pediatric intensive care unit[J]. Adv Clin Exp Med, 2019, 28(5): 615-623. PMID: 30462382. DOI: 10.17219/acem/81051.
19 Natterer J, Perez MH, Di Bernardo S. Capillary leak leading to shock in Kawasaki disease without myocardial dysfunction[J]. Cardiol Young, 2012, 22(3): 349-352. PMID: 21933461. DOI: 10.1017/S1047951111001314.
20 Druey KM, Greipp PR. Narrative review: the systemic capillary leak syndrome[J]. Ann Intern Med, 2010, 153(2): 90-98. PMID: 20643990. PMCID: PMC3017349. DOI: 10.7326/0003-4819-153-2-201007200-00005.
21 Kocak S, Acar T, Ertekin B, et al. The role of heparin-binding protein in the diagnosis of acute mesenteric ischemia[J]. Ulus Travma Acil Cerrahi Derg, 2019, 25(3): 205-212. PMID: 31135943. DOI: 10.5505/tjtes.2018.49139.
22 Liu L, Shao Y, Zhang Y, et al. Neutrophil-derived heparin binding protein triggers vascular leakage and synergizes with myeloperoxidase at the early stage of severe burns (with video)[J]. Burns Trauma, 2021, 9: tkab030. PMID: 34646891. PMCID: PMC8499692. DOI: 10.1093/burnst/tkab030.
23 Chew MS, Linder A, Santen S, et al. Increased plasma levels of heparin-binding protein in patients with shock: a prospective, cohort study[J]. Inflamm Res, 2012, 61(4): 375-379. PMID: 22207392. DOI: 10.1007/s00011-011-0422-6.
24 杨亚南, 邵换璋, 史源, 等. 肝素结合蛋白联合SOFA评分对脓毒性休克的预测价值[J]. 中华危重病急救医学, 2019, 31(3): 336-340. PMID: 30914096. DOI: 10.3760/cma.j.issn.2095-4352.2019.03.015.
25 刘双庆, 姚咏明. 中性粒细胞来源肝素结合蛋白与髓过氧化物酶协同诱发严重烧伤早期血管渗漏[J]. 中华烧伤与创面修复杂志, 2022, 38(3): 250. DOI: 10.3760/cma.j.issn.1009-2587.2022.03.106.
基金
湖南省临床医疗技术创新引导项目（2021SK50528）；湖南省卫生健康委课题项目（C2019019）。
PDF(719 KB)
